NewsBite

Stockhead

Break it Down: Invion
Stockhead

Break it Down: Invion

Invion has completed the dosing of six patients in its Phase I/II clinical trial for INV-043, treating non-melanoma skin cancers.

More Stories

Original URL: https://www.couriermail.com.au/business/stockhead/page/189